Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products


Kamada Ltd KMDA has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol TherapeuticsKamada will pay Saol a $95 million upfront payment and an additional $50 million in sales milestones during 2022-2034. 

  • The combined annual global revenue of the acquired portfolio in 2021 is expected to be $40 million - $45 million, with a gross margin of 50%-55%.
  • In addition, Kamada will acquire from Saol's existing inventory at approximately $15 million, which will be paid over ten equal quarterly installments. 
  • Kamada has secured a $40 million credit facility from Bank Hapoalim to fund the acquisition costs partially. 
  • The company says that the transaction is an important step in advancing its core objective of entering 2022 as a fully-integrated specialty plasma company.
  • Kamada reported Q3 sales of $23.0 million, -35% Y/Y, missing the consensus of $25.63 million.
  • EPS loss of $(0.02) also missed the consensus for EPS of $0.02.
  • The company held cash, cash equivalents, and short-term investments of $99.8 million at the end of Q3.
  • Price Action: KMDA shares are up 8.96% at $6.10 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLong IdeasM&ANewsHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!